Titlebook: Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract; From Surgery to Targ Eric Raymond,Sandrine Faivre,Philippe Rusznie

雜役

Cognizance

B-cell

Angiogenesis Inhibition Using Sunitinib in Pancreatic Neuroendocrine Tumors,r (VEGFR) activation for endothelial proliferation and on platelet-derived growth factor receptor (PDGFR) function for pericyte coverage. Expression of VEGF by cancer cells is thought to be induced by hypoxia-inducing factor 1 alpha that can be caused either by hypoxia or by genetic abnormalities su

的闡明

Clinical Management of Targeted Therapies in Neuroendocrine Tumours,). Clinical management of patients receiving targeted therapies aims to maximise the benefits patients achieve whilst minimising the impact of side effects to maintain quality of life. Adverse event management requires physicians to control co-morbidities, carefully review medication histories and t

HIKE

臭了生氣

Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine TumorsRecently, data from two large placebo controlled phase III trials have changed the therapeutic landscape. They demonstrated that targeted therapies directed against receptor of vascular endothelial growth factor (VEGFR) (sunitinib) and mammalian target of rapamycin (mTOR) (everolimus) produced clini

Feckless

FACT

Measuring the Relationship of Quality of Life and Health Status: Including Tumor Burden, Symptoms, as well as the social, emotional, psychological, and physical functioning of these patients. In this chapter, we describe two tools that have been developed to assess the wide spectrum of NET symptoms, determine the impact of this disease on patient’s overall well-being, and discriminate between pat